Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A

P J Baker1, J R Hiernaux, M B Fauntleroy

  • 1Laboratory of Microbial Immunity, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Insights

Nontoxic monophosphoryl lipid A (MPL) treatment inactivates suppressor T-cells, enhancing antibody responses to pneumococcal polysaccharide. These immunomodulatory effects depend on MPL dosage and timing, not B-cell activation.

Area of Science:

  • Immunology
  • Microbiology

Background:

  • Nontoxic monophosphoryl lipid A (MPL) is derived from Salmonella typhimurium.
  • Immunological paralysis can be induced by low doses of antigens.

Purpose of the Study:

  • To investigate the immunomodulatory effects of MPL on T-cell activity.
  • To determine MPL's impact on antibody response to type III pneumococcal polysaccharide.

Main Methods:

  • Treatment with MPL in mice.
  • Assessing immunological paralysis and antibody response.
  • Evaluating T-cell and B-cell activity.

Main Results:

  • MPL treatment decreased suppressor T-cell activity.
  • MPL increased antibody response to type III pneumococcal polysaccharide.
  • MPL effects were dose- and time-dependent and did not involve polyclonal B-cell activation.

Conclusions:

  • MPL effectively modulates the immune response by suppressing suppressor T-cells.
  • MPL shows potential as an immunological adjuvant or immunomodulating agent.